Phase 1 Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) Clinical Trials

2 recruitingPhase 1

What is a Phase 1 trial?

Phase 1 trials test a new treatment in a small group of people for the first time. The primary goal is to evaluate safety, determine a safe dosage range, and identify side effects. These studies typically enroll 20 to 80 participants.

Showing 1–2 of 2 trials

Recruiting

Phase 1Phase 2

TulmiSTAR-02: A Phase I/II Open-label Study of Tulmimetostat in Combination With Darolutamide vs. Darolutamide, and Tulmimetostat With Abiraterone in Patients With Metastatic Hormone-sensitive Prostate Cancer (mHSPC)

Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)

Novartis Pharmaceuticals181 enrolled31 locationsNCT07190300

Recruiting

Phase 1

Study Evaluating the Safety, Tolerability, and Efficacy of Xaluritamig in Combination With Androgen Receptor Pathway Inhibitors in Participants With Metastatic Hormone-sensitive Prostate Cancer

Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)

Amgen60 enrolled14 locationsNCT07140900